Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protective mechanism exploited by tumors may provide new cancer treatment

16.07.2004


Like a parasite exploiting its host, some tumors protect themselves by recruiting non-tumor cells that normally help keep the immune system in check, say researchers at the Medical College of Georgia.



When the researchers looked into the lymph nodes where tumors drain – typically the first place tumors spread – they found a subset of normal host immune cells were expressing IDO, an immunosuppressive enzyme also expressed by the fetus to help avoid rejection by the mother’s immune system. They also found that when they gave a drug to block IDO expression, the immune system rallied.

"Our hypothesis in this situation was that the bad guys in this case were actually cells from the host, perfectly normal cells that had, in a sense, been requested by the tumor," says Dr. David Munn, pediatric hematologist-oncologist and lead author on the study published in the July 15 issue of Journal of Clinical Investigation.


Now they have shown in an animal model that these normal cells are a type of dendritic cell that was previously ignored by the scientists because they believed the cells were involved in making antibodies not in suppressing the immune system. By recognizing the actual role of these previously discarded cells, the MCG scientists and their collaborators have moved significantly closer to using this approach to help cancer patients.

"We have demonstrated that the IDO inhibitor drug is useful in mice," says Dr. Munn. "It’s useful in a tumor model that is related to the kinds of patients we would want to treat. This brings us closer to being able to approach the FDA suggesting that IDO inhibitor drugs would be appropriate to use in patients."

The National Institutes of Health will do toxicity studies of the IDO inhibitor as well as other studies needed to take the proposal for clinical trials to the Food and Drug Administration, Dr. Munn says.

Should the FDA move toward clinical trials, it likely will be at least a year before studies begin to look at the safety and efficacy of the treatments that would help make tumors more vulnerable to the immune system, Dr. Munn says. He added that the therapy likely would be an adjunct to existing approaches such as chemotherapy and possibly a tumor vaccine that stimulates the immune response.

"It’s a general property of any tumor that survives long enough to come to medical attention that it has figured out a way to evade the immune system," Dr. Munn says. "What we would hope is that some group of tumors would rely primarily on this IDO mechanism to do that. It may not be because they are a particular type of tumor. It may be that tumors try different mechanisms and some breast cancers, colon cancers, melanomas or whatever hit on this particular strategy."

The idea of using this strategy against tumors began in 1998 when MCG scientists reported in Science that the fetus used IDO – indoleamine 2,3-dioxygenase – to locally disable the mother’s immune system and avoid rejection. The potential of using the IDO mechanism to manipulate immune response is being explored in other areas as well, such as protecting transplanted organs from rejection and helping the immune system fight HIV infection.

Fortunately, several compounds that might inhibit IDO already existed, developed as part of studying pathways involving the natural amino acid, tryptophan. Tryptophan is a precursor to the neurotransmitter, serotonin, and some popular antidepressants work by making serotonin more available to the brain. IDO suppresses the immune response by degrading tryptophan, which also is important to T cells, major orchestrators of the immune response.

The MCG researchers were able to identify and isolate the IDO-expressing cells recruited by the tumor by using state-of-the-art cell-sorting equipment purchased for MCG by the Georgia Research Alliance. "Once we had them isolated, that allowed us to test them in vitro to see if they really were suppressive like we thought," Dr. Munn says. "Then, the most convincing part of this to us was that we could transfer the cells from a mouse that had a tumor into another that didn’t and see if the immune system of the tumor-free mouse also became suppressed. And the answer was, ’Yes it did.’"

While he is excited about the potential of using the laboratory findings to help patients, Dr. Munn says the steps from bench to bedside are still complex. In the last few years, scientists have recognized that the immune system is not a passive observer. Rather, there are ongoing natural mechanisms, including IDO expression, that actively help keep the immune system tolerant. "We have to be tolerant of ourselves all the time; otherwise, you get autoimmune diseases such as arthritis and lupus," Dr. Munn says. "It’s the difference between a car that is sitting there not moving but doesn’t have on the emergency brake so it could move versus one that has on the emergency brake and can’t move until you take it off. Natural tolerance mechanisms are like a brake that must be removed before the immune system will attack the tumor.

"If you take off the brakes (for example with an IDO inhibitor drug), you may make people sick. We need to be very careful that we do not do something that causes harm to patients. So that is our next task: to test it in animal models to see if it’s a safe and appropriate thing to give patients," Dr. Munn says.

Toni Baker | EurekAlert!
Further information:
http://www.mcg.edu

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

From rocks in Colorado, evidence of a 'chaotic solar system'

23.02.2017 | Physics and Astronomy

'Quartz' crystals at the Earth's core power its magnetic field

23.02.2017 | Earth Sciences

Antimicrobial substances identified in Komodo dragon blood

23.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>